Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis group W-135 capsular polysaccharide diphtheria toxoid conjugate antigen
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Neisseria meningitidis group W-135 capsular polysaccharide diphtheria toxoid conjugate antigen** is a defined meningococcal serogroup W-135 capsular-polysaccharide antigen covalently conjugated to formaldehyde-inactivated diphtheria toxoid. It is an active antigenic constituent of Sanofi's quadrivalent Menactra vaccine, rather than a separately marketed monovalent product. Intramuscular administration of the parent vaccine induces bactericidal antibody responses directed against the serogroup W-135 capsular polysaccharide, contributing to prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroup W-135. FDA substance records identify this exact conjugate antigen as a validated active moiety, and Menactra labeling identifies it as one of four meningococcal polysaccharide-diphtheria toxoid conjugates. ([gsrs.ncats.nih.gov](https://gsrs.ncats.nih.gov/ginas/app/ui/substances/Z6R9D1D3KJ))
- Other names
- MENACTRA COMPONENTmeningococcal polysaccharide-diphtheria toxoid conjugate, group W 135Neisseria meningitidis group W-135 capsular polysaccharide diphtheria toxoid conjugate antigen
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on Neisseria meningitidis group W-135 capsular polysaccharide diphtheria toxoid conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis group W-135 capsular polysaccharide diphtheria toxoid conjugate antigen.